

# Lyudmila Bazhenova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1803719/publications.pdf>

Version: 2024-02-01

26  
papers

3,944  
citations

394421

19  
h-index

552781

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

6014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 241-251.	27.0	393
2	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
3	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i> <sup>G12C</sup> Solid Tumors (KRYSTAL-1). <i>Journal of Clinical Oncology</i> , 2022, 40, 2530-2538.	1.6	130
4	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	9.4	30
5	Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> <sup>G12C</sup> Mutation. <i>New England Journal of Medicine</i> , 2022, 387, 120-131.	27.0	269
6	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	9.4	154
7	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 21-34.	2.7	10
8	TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. <i>Targeted Oncology</i> , 2021, 16, 389-399.	3.6	24
9	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
10	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4566-4573.	7.0	13
11	An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1815-1824.	1.8	1
12	Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 56-65.	2.0	7
13	Abstract P02-01: Repotrectinib in patients with <i>NTRK</i> fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, P02-01-P02-01.	4.1	5
14	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	1.1	85
15	Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	27.0	505
16	Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 223-235.	2.1	18
17	ROS1-rearranged Non-small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 147-156.	1.0	5
18	Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 294.	4.4	45

#	ARTICLE	IF	CITATIONS
19	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901.	4.1	117
20	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	2.6	35
21	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1139-1145.	2.5	63
22	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	4.1	1,779
23	Phase 2 Study of Erlotinib in Combination With Atezolizumab (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2.	2.6	29
24	Adrenal Metastases in Lung Cancer: Clinical Implications of a Mathematical Model. <i>Journal of Thoracic Oncology</i> , 2014, 9, 442-446.	1.1	23
25	Stereotactic Body Radiation Therapy in Octogenarians With Stage I Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 131-135.	2.6	38
26	Entropy, complexity and Markov diagrams for random walk cancer models. <i>Scientific Reports</i> , 2014, 4, 7558.	3.3	28